## Mycoplasma genitalium Treatment Failure Registry

## **CASE REPORT FORM**

## The purpose of this form is to collect clinical information on cases of Mycoplasma genitalium that fail antibiotic therapy

Public reporting burden of this collection of information is estimated to average 30 minutes per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to a collection of information unless it displays a currently valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to CDC/ATSDR Reports

Clearance Officer; 1600 Clifton Road NE, MS D-74, Atlanta, Georgia 30333; Attn: OMB-PRA (0920-New) All reported information will be maintained in the strictest confidence. Questions? Contact xxx at XXX@cdc.gov Confidentiality Note: The information in this form includes confidential information intended only for the use of the individual or entity named below. If the reader of this form is not the intended recipient, you are hereby notified that any dissemination, distribution or copy of this form is strictly prohibited and may result in civil and criminal penalties under federal law. If you have received this form in error, please immediately notify us immediately at the number above PLEASE COMPLETE BY / / and fax to our confidential fax line (xxx)xxx-xxxx. **PROVIDER INFORMATION:** Provider Name Provider Phone # Provider Fax # Provider Email Address Practice/Clinic Name Address City State Zip PATIENT UNIQUE IDENTIFIER\* (First Initial, Last initial, 2-digit year of birth, last 4 digits of Medical Record Number) Example: John Smith, born 1973, MRN 1234567 = JS734567 **PATIENT AGE:** PATIENT PREVIOUSLY REPORTED TO THE REGISTRY? | Yes | No PATIENT DEMOGRAPHIC INFORMATION: 1. Race (check all that ☐ Black or African American 3a. Sex assigned at birth apply) ☐ American Indian / Alaska Native □ Male ☐ Unknown ☐ Native Hawaiian / Other Pacific ☐ Female □ White Islander 3b. Gender identity □ Asian □ Other  $\square$  Male □ Female 2. Ethnicity ☐ Transgender female ☐ Unknown ☐ Hispanic / Latino □ Not Hispanic / Latino ☐ Transgender male ☐ Gender non-binary ☐ Unknown 4. Gender of sex partners in past year (check all that apply) 5. HIV Status ☐ HIV-positive □ Male ☐ Gender non-binary ☐ HIV-negative ☐ Female Unknown □ Unknown/Never tested  $\square$  Transgender female ☐ Transgender male **DIAGNOSTICS/ TREATMENT** Indication for M. genitalium testing (check all that apply): 1) Symptoms: Urogenital (e.g., discharge, dysuria) Unanorectal (tenesmus, discharge, pain) □□Pelvic/abdominal (pain, dyspareunia) 2) Clinical Syndrome (w/ objective findings): □□Urethritis (documented discharge or pyuria) □□Cervicitis (discharge, friability, + swab test) | | PID | Proctitis | Other M. genitalium diagnosis confirmed with nucleic Laboratory performing M. genitalium testing. Testing for macrolide resistance performed? acid amplification test? (e.g., Quest, LabCorp, name of hospital, etc) ППYes П No If yes, mutation detected? ☐ Yes ☐ No ☐ Unknown ∏∏Yes ∏ No **Testing for fluroquinolone resistance performed?** □□Yes □ No If yes, mutations detected: [] S831 | [] parC unspecified Date of initial treatment initiation Date of 2<sup>nd</sup> course treatment initiation Date of 3rd course treatment initiation ☐ Unknown □ Unknown 1 1 □ Unknown Initial treatment prescribed (check all that Second treatment prescribed (check all that Third treatment prescribed (check all that apply), and dose/frequency/duration (e.g., apply), and dose/frequency/duration apply), and dose/frequency/duration doxycycline 100 mg po BID x 7 days) ☐ Azithromycin \_\_\_\_\_x days
☐ Doxycycline \_\_\_\_\_x days ☐ Azithromycin \_\_\_\_\_x days
☐ Doxycycline \_\_\_\_\_x days Azithromycin \_\_\_\_x days ☐ Moxifloxacin \_\_\_\_\_x days ☐ Doxycycline \_\_\_\_\_x days ☐ Moxifloxacin \_\_\_\_\_x days Minocycline x days ☐ Moxifloxacin \_\_\_\_\_x days ☐ Minocycline \_\_\_\_\_x days ☐ Minocycline \_\_\_\_\_x days Other \_\_\_\_\_ x davs Other \_\_\_\_\_x days ☐ Other x days

Response to initial therapy (check all that	Response to second therapy (check all that	Response to third therapy (check all that apply)
apply)	apply)	☐ Resolution of symptoms
Persistent symptoms (subjective only)	Resolution of symptoms	☐ Persistent symptoms (subjective only)
Persistent symptoms (subjective) plus objective	Persistent symptoms (subjective only)	Persistent symptoms (subjective and objective
findings (e.g, discharge, +urine dip, elevated WBC)	Persistent symptoms (subjective & objective	findings, e.g., discharge, +urine dip, elevated
☐ Positive NAAT post treatment	findings, e.g., discharge, +urine dip, elevated WBC)  ☐ Positive NAAT post treatment	WBC)  ☐ Positive NAAT post treatment
Date of 4th course treatment initiation	Date of 5 <sup>th</sup> course treatment initiation	Date of 6th course treatment initiation
	Unknown	Unknown
Fourth treatment prescribed (check all that apply), and dose/frequency/duration	Fifth treatment prescribed (check all that apply), and dose/frequency/duration	Sixth treatment prescribed (check all that apply), and dose/frequency/duration
Azithromycinx days	Azithromycinx days	☐ Azithromycinx days
☐ Doxycyclinex days	☐ Doxycyclinex days	☐ Doxycyclinex days
☐ Moxifloxacinx days	☐ Moxifloxacinx days	☐ Moxifloxacinx days
☐ Minocyclinex days	☐ Minocyclinex days	☐ Minocyclinex days
☐ Otherx days	☐ Otherx days	☐ Otherx days
Response to fourth therapy (check all that	Response to fifth therapy (check all that apply)	Response to sixth therapy (check all that apply)
apply)	Resolution of symptoms	Resolution of symptoms
☐ Resolution of symptoms	Persistent symptoms (subjective only)	☐ Persistent symptoms (subjective only)
☐ Persistent symptoms (subjective only)	Persistent symptoms (subjective and objective	☐ Persistent symptoms (subjective only)
☐ Persistent symptoms (subjective and objective	findings, e.g., discharge, +urine dip, elevated WBC)	findings, e.g., discharge, +urine dip, elevated
findings, e.g., discharge, +urine dip, elevated	☐ Positive NAAT post treatment	WBC)
WBC)		☐ Positive NAAT post treatment
Positive NAAT post treatment		
PARTNER TREATMENT		
Does patient have a primary sexual partner?     Yes   No   Unknown		
If yes, was the primary partner symptomatic? □□Yes □ No □ Unknown		
Was the primary partner treated?   Yes   No   Unknown		
If yes, was the primary partner examined by you or another clinician prior to treatment?     Yes   No   Unknown		
Partner treatment prescribed (check all that	Partner response to therapy (Check all that apply	1)
apply), and dose/frequency/duration	Resolution of symptoms	
Azithromycinx days	☐ Persistent symptoms (subjective only)	
Doxycyclinex days	Persistent symptoms (subjective and objective findings, e.g., discharge, +urine dip, elevated WBC)	
☐ Moxifloxacinx days	☐ Positive NAAT post treatment	
☐ Minocyclinex days	☐ Unknown, partner not examined	
Otherx days	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	
	If partner has persistent symptoms or NAAT following therapy, please complete a separate case report form for the partner.	
Notes:		

Version date 05/08/2020